10 Biotech Stocks With Catalysts Coming Soon – Benzinga

Related CLVSClovis Oncology Could Pass $100 By Year-End: Here’s WhyClovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLCClovis Oncology: Don’t Discount Rociletinib’s Chances Against AZD9291(Seeking Alpha)Related EPZMBenzinga’s Top DowngradesH.C. Wainwright Destroys Epizyme Price Target, Sees ‘No Material Value Drivers’A new report by Mizuho analyst Peter Lawson focuses on biotech stocks with major catalysts […]